Synonyms: GS-6207 | GS6207 | Sunlenca®
lenacapavir is an approved drug (EMA & FDA (2022))
Compound class:
Synthetic organic
Comment: Lenacapavir (GS-6207) is a novel long-acting anti-HIV lead that binds to the virus' at a conserved interface between capsid protein monomers [2]. This mechanism disrupts early and late phases of the viral replication cycle [1] [3]. PDB entry 6V2F shows the crystal structure of lenacapavir-bound HIV capsid hexamer.
|
|
References |
1. Freed EO. (2015)
HIV-1 assembly, release and maturation. Nat Rev Microbiol, 13 (8): 484-96. [PMID:26119571] |
2. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, Begley R, Chiu A, Mulato A, Hansen D et al.. (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature, 584 (7822): 614-618. [PMID:32612233] |
3. Thenin-Houssier S, Valente ST. (2016)
HIV-1 Capsid Inhibitors as Antiretroviral Agents. Curr HIV Res, 14 (3): 270-82. [PMID:26957201] |